Avaxia Biologics
Stage
Series B - III | AliveTotal Raised
$24.94MLast Raised
$1.01M | 8 yrs agoAbout Avaxia Biologics
Avaxia is an early-stage biotechnology company focused on developing recombinant, gut-targeted antibody therapeutics for gastrointestinal diseases. These unique antibody therapeutics, called Avaximabs, are orally administered, minimally absorbed drugs that act locally in the gastrointestinal (GI) tract. Avaxia believes that treatment of GI diseases with gut-targeted antibodies has the potential to address important limitations of existing therapies.
Missing: Avaxia Biologics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Avaxia Biologics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Avaxia Biologics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Avaxia Biologics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Avaxia Biologics Patents
Avaxia Biologics has filed 14 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/10/2014 | 7/14/2015 | Digestive system, Autoimmune diseases, Gastrointestinal tract disorders, Inflammations, Clusters of differentiation | Grant |
Application Date | 1/10/2014 |
---|---|
Grant Date | 7/14/2015 |
Title | |
Related Topics | Digestive system, Autoimmune diseases, Gastrointestinal tract disorders, Inflammations, Clusters of differentiation |
Status | Grant |
Latest Avaxia Biologics News
Feb 5, 2017
Avaxia Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 10:50 EST 5 Feb 2017 | BioPortfolio Reports Home » Topics » Biotherapeutics » Latest News » Avaxia Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Avaxia Biologics Inc Avaxia is a biotechnology company that provides solutions for guttargeted antibody therapeutics. The company uses proprietary technology platform to develop recombinant, guttargeted antibody therapeutics, called avaximabs. Its avaximabs provide ability to neutralize GItract receptors and ligands; maintain longterm efficacy, enabling combination therapy and providing solutions for oral dosage forms. Avaxia offers its avaximabs through capsules or specialized liquid formulations. The company's product provides new opportunities for therapeutic intervention for many serious diseases. It also offers research services in treatment areas of inflammatory bowel disease, GI inflammatory diseases, celiac diseases and microbiomes. Avaxia is headquartered in Lexington, Massachusetts, the US. Avaxia Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Avaxia Biologics Frequently Asked Questions (FAQ)
Where is Avaxia Biologics's headquarters?
Avaxia Biologics's headquarters is located at 128 Spring Street, Lexington.
What is Avaxia Biologics's latest funding round?
Avaxia Biologics's latest funding round is Series B - III.
How much did Avaxia Biologics raise?
Avaxia Biologics raised a total of $24.94M.
Who are the investors of Avaxia Biologics?
Investors of Avaxia Biologics include Golden Seeds, Cherrystone Angel Group, Medica Partners, AbbVie Biotech Ventures, Maine Angels and 17 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.